The stock's rise snapped an eight-day losing streak.

On Friday, Ocugen Inc (OCGN) stock saw a modest uptick, ending the day at $0.71 which represents no change from the prior close of of $0.71. The stock opened at $0.72 and touched a low of $0.7 during ...

Ocugen, Inc. (NASDAQ: OCGN) this week announced the dosing of the first patient in its Phase 1 clinical trial for OCU200, a ...

Ocugen, Inc. (NASDAQ: OCGN) has announced a positive 2-year safety and efficacy update from its Phase 1/2 clinical trial for ...

Shares of Ocugen Inc. OCGN slid 1.91% to $0.72 Thursday, on what proved to be an all-around rough trading session for the ...

Ocugen (OCGN) announced that the first patient has been dosed in the OCU200 Phase 1 clinical trial for diabetic macular edema, DME. “OCU200 has ...

Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and ...

In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Ocugen (OCGN – Research Report), with a ...

OCU410 has a very favorable safety and tolerability profileNo serious adverse events related to the study drug have been reported, such as exudation, infectious endophthalmitis, intraocular ...

It is a good idea to keep an eye on five biotech breakthrough stocks, MDMD, BEAM, ACLX, OCGN and INSM, as they may give great returns in the next 2-3 years On September 30, 2024, State Street Corp ...